ArQule, Inc. (NASDAQ:ARQL)

CAPS Rating: 2 out of 5

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

Recs

0
Player Avatar barrettfodder (67.54) Submitted: 6/21/2007 9:59:17 AM : Outperform Start Price: $7.62 ARQL Score: -15.37

If the next phase of clinical trials goes well. This company will be set for the remainder of its life. Worth a look

Featured Broker Partners


Advertisement